Advanced Search
ViThera Pharmaceuticals

ViThera Pharmaceuticals

A pharmaceutical company that combines probiotics with synthetic biology to create novel therapeutics for chronic diseases. The underlying concept of their strategies is to used genetically engineered probiotic bacteria as vectors for the delivery of therapeutic proteins for the treatment of inflammatory bowel disease.

Edit ID  15859456 

Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 1 May, 2020
Edits made to:
Article (+14/-14 characters)

Johannes Fruehauf, Founder of ViThera was previously employed by Cequent Pharmaceuticals. Cequent merged with MDRNA and the combined firm was renamed Marina BiotechMarina Biotech. ViThera employed some former researchers from the company Cequent, which developed engineered E. Coli bacteria for the delivery of RNA-interference (RNAi) drugs to the gut called transkingdom RNAi (tkRNAi). ViThera conducted contract research to partially fund its own projects and served clients focused on RNAi, and that side of the business has been renamed Cambridge Biolabs. Cambridge Biolabs maintains a license to tkRNAi and Marina Biotech is eligible for milestone and royalty payments from those programs. Cambridge Biolabs continues to provide custom laboratory services and is independent from ViThera.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.